Replies to post #7485 on $Amazing $Biotech & $olid $Microcap $tocks

[BottomBounce]

CBD Life Sciences Inc. $CBDL through its wholly owned subsidiary "LBC Bioscience Inc." is pleased to announce that our "PROPRIETARY 100 MG PURE CBD TABLETS" has finally arrived to our Facility and is ready to be shipped out to consumers. The product consists of 100 MG CBD tablets 10 count in each container. This extraordinary product can help consumers relive pain, ease muscle soreness, inflammation, tension and more. Consumers can place their order today on our website www.lbcbioscienceinc.com. CBD (Cannabidiol) has shown promising indication for the health & wellness industry and has become increasingly widespread throughout the public.

WEBSITE _https://www.lbcbioscienceinc.com

[BottomBounce]

$MJNA Website: https://www.medicalmarijuanainc.com

[BottomBounce]

Ford $F Ford's new no-service navigation will help adventurers stay on course https://www.autoblog.com/2020/07/29/ford-trail-nav-sync4/

[Ecomike]

$NDTP is a sleeper folks, this Dr. Mark Kester just arrived on the new Team member page of the 8 week old web site. (Reminder MILV was the custodial shell take over I mentioned here 6 months ago that is now $NDTP a real biotech)

https://pubmed.ncbi.nlm.nih.gov/29408569/

"Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice" This may be the one in a FDA phase II drug trial now.

https://www.keystonenano.com/

Did $NDTP buy Keystonenano?

The question came up when out NDTP DD team noticed, while DD'ing Dr. Mark Kester and Keystone Nano, that weeks after Keystone Nano went dark on all social media (where they had been very active) Last September, the Private Biotech CCA, LLC began the take over and clean up a dead OTC shell to go public.

2 weeks ago the Team list was added to the NDTP website.

7 days ago the 27.5 Mil $4/shares were added to the OS.

Coincidence????

10 Mil of those shares could have been cash at $4/share.

WE are waiting for the Final SEC 1-A filing that takes the 15-12g stock back to fully SEC reporting, probably in an NYSE over night up list.

DJM...., Interesting

"Antibe Therapeutics $ATBPF"

I all to aware of the dangers of NSAIDS so I will check it out. See you on the $ATBPF board!

[BottomBounce]

$PMCB Bio-Artificial Pancreas for Diabetes

"We plan to develop a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Our therapy involves encapsulation of human cells that have been genetically engineered to produce, store insulin and release insulin on demand at levels in proportion to the levels of blood sugar (glucose) in the human body. We also plan to explore the encapsulation of human stem cells and beta islet cells as an alternative to using genetically modified human liver cells. The encapsulation will be done using the Cell-in-a-Box® technology.

Insulin-producing cells (HIT-T15) have already been encapsulated using the sodium cellulose sulfate-based technology found in Cell-in-a-Box®. Encapsulation did not affect cell viability or insulin production. In cell culture, the encapsulated cells were able to detect the glucose concentration in a nutrient solution and react in a proper way by producing insulin. In the opinion of the authors of the study, encapsulation of insulin-producing cells with sodium cellulose sulfate, which is more biocompatible and less immunogenic than other encapsulation materials, seemed to be a promising method for the immunoisolation of porcine beta islet cells for xenotransplantation to replace the endocrine pancreas. Schaffellner S., et al.
Transplantation Proc., Vol. 37, 248-252 (2005)

In an effort to avoid the use of non-human islet cells in its diabetes treatment, PharmaCyte has obtained from the University of Technology Sydney (“UTS”) in Australia an exclusive, worldwide license to use insulin-producing genetically engineered human liver cells developed by UTS to treat Type 1 diabetes and insulin-dependent Type 2 diabetes. These cells, named “Melligen,” have already been tested in mice and shown to produce insulin in direct proportion to the amount of glucose in their surroundings. In fact, when Melligen cells were transplanted into immosuppressed diabetic mice, their blood glucose levels became normal. The Melligen cells reversed the diabetic condition.

Melligen cells can be readily grown in culture and are available in unlimited supply. Compared to native pancreatic beta islet cells, Melligen cells are much more resistant to the pro-inflammatory cytokines that have been shown to be involved in beta islet cell death. We believe that this property makes them an ideal potential candidate cell line for beta islet cell replacement therapy with the prospect to achieve long-term transplant graft function. However, further research and development (“R&D”) needs to be done with the Melligen cells to insure they function as reported in the literature by UTS.

PharmaCyte has acquired from Austrianova an exclusive, worldwide license to use the Cell-in-a-Box® technology for the development of a treatment for diabetes. We believe that encapsulating the Melligen cells using Cell-in-a-Box® live cell encapsulation technology has numerous advantages over encapsulation of cells with other materials, such as alginate. Since our capsules are composed largely of cellulose (a bio-inert material in the human body), the Cell-in-a-Box® capsules are durable, resilient and long-lasting when compared to the competition. They remain intact for long periods of time in the body, all the while protecting the cells inside them from immune system attack. Also, in prior studies these capsules and the cells inside them have not caused any immune or inflammatory responses like those seen with alginate-encapsulated cells. Studies have shown that the Cell-in-a-Box encapsulation process does not reduce the capability of the Melligen cells to produce insulin."

https://pharmacyte.com/live-cell-encapsulation/diabetes/

[BottomBounce]

$MJNA First to Introduce Cannabinoid Foods and Supplements to the Mainstream Marketplace
Recognizing the need for a national cannabinoid market to create access to cannabinoids to as many people as possible, despite the legal challenges, Medical Marijuana, Inc. began researching ways to bring cannabis-based products to a wider customer base. https://www.medicalmarijuanainc.com/company-of-firsts/the-first-to-introduce-cannabinoids-to-the-mainstream-marketplace/

[BottomBounce]

$CEMI Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.